Clinical Trial Update: Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating ceritinib in ALK- and ROS1-activated gastrointestinal cancers has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Colorectal Cancer
• Esophageal Cancer
• Gastric Cancer
• Hepatocellular Carcinoma
• Pancreatic Cancer

Drugs mentioned

• Ceritinib (ceritinib)

Snippet

Sponsor: Criterium, Inc. | Conditions: Colorectal Adenocarcinoma, Cholangiocarcinoma | Phase 2 | Status: TERMINATED